<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38052015</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1464-3685</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of epidemiology</Title><ISOAbbreviation>Int J Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Prevalence and determinants of post-acute sequelae of COVID-19 in Liberia.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">dyad167</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ije/dyad167</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Evidence from resource-rich settings indicates that many people continue to have persistent symptoms following acute SARS-CoV-2 infection, called post-acute sequelae of COVID-19 (PASC). Only a few studies have described PASC in sub-Saharan Africa (SSA). We aimed to describe PASC in Liberia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We randomly sampled all people who were reported from the most populous county to the Liberian Ministry of Health (MOH) as having a laboratory-confirmed SARS-CoV-2 infection from June to August 2021. We interviewed individuals by phone 3 to 6&#x2009;months later. Those with persistence of at least one symptom were considered to have PASC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From among 2848 people reported to the MOH from Montserrado County during the period of interest, we randomly selected 650; of these, 548 (84.3%) were reached and 505 (92.2%) of those who were contacted were interviewed. The median age was 38&#x2009;years (interquartile range (IQR), 30-49), and 43.6% were female. During acute infection, 40.2% were asymptomatic, 53.9% had mild/moderate disease and 6.9% had severe/critical disease. Among the 59.8% (n&#x2009;=&#x2009;302) who were initially symptomatic, 50.2% (n&#x2009;=&#x2009;152) reported at least one persistent symptom; the most common persistent symptoms were fatigue (21.2%), headache (16.2%) and cough (12.6%); 40.1% reported that PASC significantly affected their daily activities. Being hospitalized with moderate disease [adjusted prevalence ratio (aPR), 2.00 (95% CI, 1.59 to 2.80] or severe/critical disease [aPR, 2.11 (95% CI, 1.59 to 2.80)] was associated with PASC, compared with those not hospitalized. Females were more likely than males to report persistent fatigue [aPR, 1.67 (95% CI, 1.08 to 2.57)].</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that persistent symptoms may have affected a large proportion of people with initially symptomatic COVID-19 in west Africa and highlight the need to create awareness among infected people and health care professionals.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gwaikolo</LastName><ForeName>Cozie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sackie-Wapoe</LastName><ForeName>Yatta</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Montserrado County Health Team, Ministry of Health, Monrovia, Liberia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badio</LastName><ForeName>Moses</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, Liberia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glidden</LastName><ForeName>David V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindan</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Global Health Sciences, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R25 MH123256</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U2R TW011281</GrantID><Acronym>TW</Acronym><Agency>FIC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25MH123256</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5U2RTW011281</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Epidemiol</MedlineTA><NlmUniqueID>7802871</NlmUniqueID><ISSNLinking>0300-5771</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007988" MajorTopicYN="N" Type="Geographic">Liberia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Africa</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of COVID-19</Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>11</Day><Hour>16</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>6</Day><Hour>3</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>5</Day><Hour>16</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38052015</ArticleId><ArticleId IdType="pmc">PMC10859153</ArticleId><ArticleId IdType="doi">10.1093/ije/dyad167</ArticleId><ArticleId IdType="pii">7459210</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Johns Hopkins Coronavirus Resource Centre. COVID-19 Dashboard. 2022. https://coronavirus.jhu.edu/map.html (18 December 2022, date last accessed).</Citation></Reference><Reference><Citation>Havers FP, Reed C, Lim T. et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12, 2020. JAMA Intern Med 2020;180:1576&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">32692365</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber RM, Sorensen RJD, Pigott DM. et al. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet 2022;399:2351&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8993157</ArticleId><ArticleId IdType="pubmed">35405084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau H, Khosrawipour T, Kocbach P, Ichii H, Bania J, Khosrawipour V.. Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters. Pulmonology 2021;27:110&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275155</ArticleId><ArticleId IdType="pubmed">32540223</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. Over two-thirds of Africans exposed to virus which causes COVID-19: WHO study. 2022. https://www.afro.who.int/news/over-two-thirds-africans-exposed-virus-which-causes-covid-19-who-study (25 August 2022, date last accessed).</Citation></Reference><Reference><Citation>Cabore JW, Karamagi HC, Kipruto HK. et al. COVID-19 in the 47 countries of the WHO African region: a modelling analysis of past trends and future patterns. Lancet Glob Health 2022;10:e1099&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9159735</ArticleId><ArticleId IdType="pubmed">35659911</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobia F, Gitaka J.. COVID-19: Are Africa's diagnostic challenges blunting response effectiveness? AAS Open Res 2020;3:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205356</ArticleId><ArticleId IdType="pubmed">32399515</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran AV, Jayadevan R, Sashidharan S.. Long COVID: An overview. Diabetes Metab Syndr 2021;15:869&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D, Nicholson TR, Needham DM. et al. Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development. BMC Med 2022;20:50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8813480</ArticleId><ArticleId IdType="pubmed">35114994</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D, O'Hara ME, Akrami A, Perego E, Olliaro P, Needham DM.. Long COVID: aiming for a consensus. Lancet Respir Med 2022;10:632&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9067938</ArticleId><ArticleId IdType="pubmed">35525253</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel K, Pinto C. et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J Med Virol 2022;94:253&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B.. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022;226:1593&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkodaymi MS, Omrani OA, Fawzy NA. et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect 2022;28:657&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8812092</ArticleId><ArticleId IdType="pubmed">35124265</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med 2022;28:1706&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Crankson S, Pokhrel S, Anokye NK.. Determinants of COVID-19-related length of hospital stays and long COVID in Ghana: a cross-sectional analysis. Int J Environ Res Public Health 2022;19:527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8744866</ArticleId><ArticleId IdType="pubmed">35010786</ArticleId></ArticleIdList></Reference><Reference><Citation>Dryden M, Mudara C, Vika C. et al. Post COVID-19 condition in South Africa: 3-month follow-up after hospitalisation with SARS-CoV-2. Lancet Glob Health 2022;10:e1247&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9363040</ArticleId><ArticleId IdType="pubmed">35961348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zulu JE, Banda D, Hines JZ. et al. Two-month follow-up of persons with SARS-CoV-2 infection-Zambia, September 2020: a cohort study. Pan Afr Med J 2022;41:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8895565</ArticleId><ArticleId IdType="pubmed">35291364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigfrid L, Drake TM, Pauley E, ISARIC4C investigators et al.Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Lancet Reg Health Eur 2021;8:100186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C, Pellicer-Valero OJ, Navarro-Pardo E. et al. Symptoms Experienced at the Acute Phase of SARS-CoV-2 Infection as Risk Factor of Long-term Post-COVID Symptoms: The LONG-COVID-EXP-CM Multicenter Study. Int J Infect Dis 2022;116:241&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8743274</ArticleId><ArticleId IdType="pubmed">35017102</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG, Brokstad KA. et al.; Bergen COVID-19 Research Group. Long COVID in a prospective cohort of home-isolated patients. Nat Med 2021;27:1607&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell ML, Catalfamo CJ, Farland LV. et al. Post-acute sequelae of COVID-19 in a non-hospitalized cohort: results from the Arizona CoVHORT. PLoS One 2021;16:e0254347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8336814</ArticleId><ArticleId IdType="pubmed">34347785</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM; Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet 2022;400:452&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Yomogida K, Zhu S, Rubino F, Figueroa W, Balanji N, Holman E.. Post-acute sequelae of SARS-CoV-2 infection among adults aged &#x2265;18 years &#x2014;Long Beach, California, April 1&#x2013;December 10, 2020. MMWR Morb Mort Wkly Rep 2021;70:1274&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445372</ArticleId><ArticleId IdType="pubmed">34529639</ArticleId></ArticleIdList></Reference><Reference><Citation>Osikomaiya B, Erinoso O, Wright KO. et al. &#x2018;Long COVID&#x2019;: persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis 2021;21:304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7993075</ArticleId><ArticleId IdType="pubmed">33765941</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendelsohn AS, Nath N, De Sa A, von Pressentin KB.. Two months follow-up of patients with non-critical COVID-19 in Cape Town, South Africa. S Afr Fam Pract (2004) 2022;64:e1&#x2013;e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8905322</ArticleId><ArticleId IdType="pubmed">35144461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wose Kinge C, Hanekom S, Lupton-Smith A. et al. Persistent symptoms among frontline health workers post-acute COVID-19 infection. Int J Environ Res Public Health 2022;19:5933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9140668</ArticleId><ArticleId IdType="pubmed">35627472</ArticleId></ArticleIdList></Reference><Reference><Citation>Shobayo B, Mishra M, Sameroff S. et al. SARS-CoV-2 sequence analysis during COVID-19 case surge, Liberia, 2021. Emerg Infect Dis 2021;27:3185&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632187</ArticleId><ArticleId IdType="pubmed">34708683</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for Human Research Protections USDoHaHS. US 2018 Revised CommonRule.2021. https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html (6 July 2023, date last accessed).</Citation></Reference><Reference><Citation>Shepherd BE, Rebeiro PF, Caribbean C; South America Network for HIVe. Brief Report: Assessing and interpreting the association between continuous covariates and outcomes in observational studies of HIV using splines. J Acquir Immune Defic Syndr 2017;74:e60&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5303133</ArticleId><ArticleId IdType="pubmed">27798430</ArticleId></ArticleIdList></Reference><Reference><Citation>
Stata. Margins&#x2013;Marginal Means, Predictive Margins, and Marginal Effects. 2023. https://www.stata.com/manuals/rmargins.pdf (2 July 2023, date last accessed).</Citation></Reference><Reference><Citation>Snowden JM, Rose S, Mortimer KM.. Implementation of G-computation on a simulated data set: demonstration of a causal inference technique. Am J Epidemiol 2011;173:731&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3105284</ArticleId><ArticleId IdType="pubmed">21415029</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindan CP, Desai M, Boothroyd D. et al. Design of a population-based longitudinal cohort study of SARS-CoV-2 incidence and prevalence among adults in the San Francisco Bay Area. Ann Epidemiol 2022;67:81&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8596645</ArticleId><ArticleId IdType="pubmed">34800659</ArticleId></ArticleIdList></Reference><Reference><Citation>Badio M, Johnson K, Mlie J, et al. Performance of a rapid antigen test compared to PCR for diagnosis of SARS-CoV-2 infection in Liberia. West African Consortium for Clinical Research on Epidemic Pathogens (WAC-CREP) 5th International Conference; 2022 March 17&#x2013;19. Yamoussoukro, Ivory Coast.</Citation></Reference><Reference><Citation>Seessle J, Waterboer T, Hippchen T. et al. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clin Infect Dis 2022;74:1191&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera Martimbianco AL, Pacheco RL, Bagattini AM, Riera R.. Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. Int J Clin Pract 2021;75:e14357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8236920</ArticleId><ArticleId IdType="pubmed">33977626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira JC, Moreira TCL, de Araujo AL. et al. Clinical, sociodemographic and environmental factors impact post-COVID-19 syndrome. J Glob Health 2022;12:05029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9359428</ArticleId><ArticleId IdType="pubmed">35939273</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan A. Long-term outcomes from critical care. Surgery (Oxf) 2021;39:53&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836934</ArticleId><ArticleId IdType="pubmed">33519011</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L, Baca S, Saydah S. et al. Post-COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years&#x2013;United States, March 2020&#x2013;November 2021. MMWR Morb Mortal Wkly Rep 2022;71:713&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9368731</ArticleId><ArticleId IdType="pubmed">35925799</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (23 August 2022, date last accessed).</Citation></Reference><Reference><Citation>Hanson WS, Abbafati C, Aerts JG. et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. 2022;328:1604&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Sylvester SV, Rusu R, Chan B, Bellows M, O'Keefe C, Nicholson S.. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review. Curr Med Res Opin 2022;38:1391&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">35726132</ArticleId></ArticleIdList></Reference><Reference><Citation>Usuf E, Roca A.. Seroprevalence surveys in sub-Saharan Africa: what do they tell us? The Lancet Global Health 2021;9:e724&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">33711261</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. Coronavirus (COVID-19) Dashboard. 2022. https://covid19.who.int (11 January 2022, date last accessed).</Citation></Reference><Reference><Citation>Hastie CE, Lowe DJ, McAuley A. et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun 2022;13:5663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>El Otmani H, Nabili S, Berrada M, Bellakhdar S, El Moutawakil B, Abdoh Rafai M.. Prevalence, characteristics and risk factors in a Moroccan cohort of Long-Covid-19. Neurol Sci 2022;43:5175&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132567</ArticleId><ArticleId IdType="pubmed">35614173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen AIV, Spiliopoulos L, Bager P. et al. A nationwide questionnaire study of post-acute symptoms and health problems after SARS-CoV-2 infection in Denmark. Nat Commun 2022;13:4213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9302226</ArticleId><ArticleId IdType="pubmed">35864108</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ.. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022;399:2263&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B, Bluemke DA, Luscher TF, Neubauer S.. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J 2022;43:1157&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903393</ArticleId><ArticleId IdType="pubmed">35176758</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Self WH, Adams K. et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA 2021;326:2043&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8569602</ArticleId><ArticleId IdType="pubmed">34734975</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB. et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ 2022;377:e069676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>
The World Bank. Liberia Demographic and Health Survey 2019&#x2013;2020. 2021. https://microdata.worldbank.org/index.php/catalog/3896 (15 April 2021, date last accessed).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>